



Sandwich-Elisa of Several A β -Forms with Biotinylated
 Clone 8F5 Coated Clone 6G1
 coated anti-A β clone 6G1 --> A β -Forms --> biotinylated clone
 8F5 --> Streptavidin-POD --> development



	A β (1-42) oligomer	HFIP monomer A β (1-42)	NH ₄ OH monomer A β (1-40)	HFIP monomer A β (1-40)
BOTTOM	-0.001218	0.004304	0.006727	0.004288
TOP	0.9926	1.002	0.9292	0.1116
LOGEC50	1.958	2.745	3.003	2.825
HILLSLOPE	1.215	1.270	1.204	1.375
EC50	90.74	555.8	1007	667.8

FIG.1



1. Marker
2. Fibril preparation control
3. Fibril preparation ; + mMAb 6E10 ; 20h 37°C ; supernatant
4. Fibril preparation ; + mMAb 6E10 ; 20h 37°C ; pellet
5. Fibril preparation ; + mMAb 4G8 ; 20h 37°C ; supernatant
6. Fibril preparation ; + mMAb 4G8 ; 20h 37°C ; pellet
7. Fibril preparation ; + mMAb 8F5 ; 20h 37°C ; supernatant
8. Fibril preparation ; + mMAb 8F5 ; 20h 37°C ; pellet

FIG.2

3/14





FIG.3



*** $P < 0.001$ vs. 50%
o $P < 0.05$; oo $P < 0.01$
post hoc t-test vs. PBS after $P < 0.001$ in ANOVA

FIG.4

VH 8F5

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGCCC
 TGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATGGCATGTCT
TGGGTCGCCAGACTCCAGACAAGAGGCTGGAATTGGTCGCAAGCATCAATA
GTAATGGTGGTAGCACCTATTATCCAGACAGTGTGAAGGGCCGATTCACCAT
 CTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAAG
 TCTGAGGACACAGCCATGTATTACTGTGCAAGTGGTGA~~CTACT~~GGGGCCAAG
 GCTCCACTCTCACAGTCTCCTCA (SEQ ID NO:1)

FIG.5A

VL 8F5

GATGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCA
 AGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTATATAGTAATGGAGACA
CCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATC
TACAAAGTTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTG
 GATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGGAGGCTGAGGATCT
 GGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCTTGGACGTTTCGGTGGAG
 GCACCAAGCTAGAAATCAAACGG (SEQ ID NO:2)

FIG.5B

VH 8F5

EVQLVESGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLELVASINSN
GGSTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASGDYWGQGST
LTVSS (SEQ ID NO:3)

CDR1 (VH) = SYGMS (SEQ ID NO:5)
CDR2 (VH) = SINSNGGSTYYPDSVKG (SEQ ID NO:6)
CDR3 (VH) = SGDY (SEQ ID NO:7)

FIG.6A

VL 8F5

DVVMQTPLSLPVSLGDQASISCRSSQSLVYSNGDTYLHWYLQKPGQSPKLLIYK
VSNRFSGVDPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLE
IKR (SEQ ID NO:4)

CDR1(VL) = RSSQSLVYSNGDTYLH (SEQ ID NO:8)
CDR2(VL) = KVSNRFS (SEQ ID NO:9)
CDR3(VL) = SQSTHVPWT (SEQ ID NO:10)

FIG.6B

7/14




FIG.7A

8/14




FIG.7B

9/14





FIG.7C


Binding to amyloid plaques in Tg2576



Antibody

FIG.7D


Binding to amyloid plaques in AD (RZ55)



Antibody

FIG.7F


Binding to amyloid plaques in APP/L



concentration [$\mu\text{g/ml}$]

FIG.7E

Binding to amyloid plaques in AD (RZ16)



concentration [$\mu\text{g/ml}$]

FIG.7G

11/14





FIG.7H

Sandwich-Elisa of Several A β -Forms with Biotinylated
Coated Clones

coated anti-A β clone 6G1 ---> A β -Forms ---> biotinylated clone
8C5 ---> Streptavidin-POD ---> development



	A β (1-42)	globulomer	A β (1-42)	HFIP monomer	A β (1-42)	NH ₄ OH monomer	A β (1-40)	HFIP monomer	sAPP?
BOTTOM	0.0003317	0.005757	-0.008508	0.0002754	0.0003000				
TOP	1.601	1.545	1.137	0.2455	0.06415				
LOGEC50	2.755	3.370	4.505	3.794	3.237				
HILLSLOPE	1.369	1.377	1.052	0.9842	1.197				
EC50	568.2	2346	31991	6222	1725				

FIG.8

VH 8C5

GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCC
TGAAACTCTCCTGTACAGCCTCTGGATTCACTTTCAGTAGCTATGGCATGTCT
TGGGTTCCGACACTCCAGACAAGAGGCTGGAGTTGGTCGCAAGTATTA
ATAATGGTGGTAGCACCTATTATCCAGACAGTTTGAAGGGCCGATTCACCAT
CTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAAG
TCTGAGGACACAGCCATGTATTATTGTGCAAGTGGGGATTACTGGGGCCAAG
GCACCACTCTCACAGTCTCCTCA (SEQ ID NO:11)

FIG.9A

VL 8C5

GATGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCA
AGCCTCCATCTCTTGAGATCTAGTCAGAGCCTTGTACACAGTAATGGAGAC
ACCTTTTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGAT
CTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAAGTGGCAGTG
GATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGGAGGCTGAGGATCT
GGGAATTTATTTCTGCTCTCAGAGTATACATGTTCCGTGGACGTTCCGGTGGAG
GCACCAAGCTGGAAATCAAACGG (SEQ ID NO:12)

FIG.9B

VH 8C5

EVQLVESGGGLVQPGGSLKLSCTASGFTFSSYGMSWVRQTPDKRLELVASIKNN
GGSTYYPDLSLKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASGDYWGQGTT
LTVSS (SEQ ID NO:19)

CDR1 (VH) = SYGMS (SEQ ID NO:13)

CDR2 (VH) = SIKNNGGSTYYPDSLKG (SEQ ID NO:14)

CDR3 (VH) = SGDY (SEQ ID NO:15)

FIG.10A

VL 8C5

DVVMQTPLSLPVSLGDQASISCRSSQSLVHSNGDTFLHWYLQKPGQSPKLLIYK
VSNRFSGVPRFSGSGSGTDFTLKISRVEAEDLGIYFCSQSIHVPWTFGGGTKLEI
KR (SEQ ID NO:20)

CDR1 (VL) = RSSQSLVHSNGDTFLH (SEQ ID NO:16)

CDR2 (VL) = KVSNRFS (SEQ ID NO:17)

CDR3 (VL) = SQSIHVPWT (SEQ ID NO:18)

FIG.10B